Icon Group has announced the completion of a debt raising totalling $810 million to support strategic expansion into Asia to meet the growing cancer burden in the region.
Icon Group will use the funds to repay existing debt and continue to invest in the Group’s vision of ensuring as many people as possible have timely access to quality oncology specialists and world class technology. The move to a Term Loan B structure also provides the Group with additional flexibility to strengthen services across cancer care, hospital pharmacy and chemotherapy compounding, and build new cancer centres in Australia, Singapore and China.
